MX2023000679A - Inhibidores del factor c3 del complemento y sus usos medicos. - Google Patents

Inhibidores del factor c3 del complemento y sus usos medicos.

Info

Publication number
MX2023000679A
MX2023000679A MX2023000679A MX2023000679A MX2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A MX 2023000679 A MX2023000679 A MX 2023000679A
Authority
MX
Mexico
Prior art keywords
compstatin
analogues
complement
introduction
inhibiting activity
Prior art date
Application number
MX2023000679A
Other languages
English (en)
Spanish (es)
Inventor
Anne Pernille Tofteng Shelton
Henrik Fischer Munch
Rasmus Leth
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of MX2023000679A publication Critical patent/MX2023000679A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
MX2023000679A 2020-07-16 2021-07-15 Inhibidores del factor c3 del complemento y sus usos medicos. MX2023000679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20186297 2020-07-16
PCT/EP2021/069798 WO2022013374A1 (en) 2020-07-16 2021-07-15 Inhibitors of complement factor c3 and their medical uses

Publications (1)

Publication Number Publication Date
MX2023000679A true MX2023000679A (es) 2023-04-18

Family

ID=71661768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000679A MX2023000679A (es) 2020-07-16 2021-07-15 Inhibidores del factor c3 del complemento y sus usos medicos.

Country Status (11)

Country Link
US (1) US20230287051A1 (cg-RX-API-DMAC10.html)
EP (1) EP4182023A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023538807A (cg-RX-API-DMAC10.html)
KR (1) KR20230039718A (cg-RX-API-DMAC10.html)
CN (1) CN116209671A (cg-RX-API-DMAC10.html)
AU (1) AU2021309548A1 (cg-RX-API-DMAC10.html)
CA (1) CA3185730A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001411A2 (cg-RX-API-DMAC10.html)
IL (1) IL299870A (cg-RX-API-DMAC10.html)
MX (1) MX2023000679A (cg-RX-API-DMAC10.html)
WO (1) WO2022013374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017385A2 (pt) 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
CN119219741A (zh) * 2023-06-29 2024-12-31 刘晓蓉 新型补体抑制剂及其制备、应用和产品
CN122255228A (zh) * 2024-12-20 2026-06-23 重庆派金生物科技有限公司 靶向抑制c3与c5补体的双功能多肽、多肽偶联物及它们的应用
US20260234189A1 (en) 2025-01-24 2026-08-13 Boehringer Ingelheim International Gmbh Novel and stable compstatin analogues

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ES2390828T3 (es) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
EP2751161B1 (en) * 2011-08-31 2018-09-19 Huntsmann Advanced Materials Licensing (Switzerland) GmbH Process for the impregnation of air core reactors, impregnated air core reactor and use of an impregnation system
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
US10213476B2 (en) * 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
BR112020017385A2 (pt) * 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
ES3049784T3 (en) * 2019-08-27 2025-12-18 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
US20230287051A1 (en) 2023-09-14
CA3185730A1 (en) 2022-01-20
EP4182023A1 (en) 2023-05-24
CO2023001411A2 (es) 2023-02-16
CN116209671A (zh) 2023-06-02
JP2023538807A (ja) 2023-09-12
KR20230039718A (ko) 2023-03-21
WO2022013374A1 (en) 2022-01-20
AU2021309548A1 (en) 2023-02-23
IL299870A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
CO2023001411A2 (es) Inhibidores del factor c3 del complemento y sus usos médicos
AU2011325910B2 (en) Cancer therapies and diagnostics
MX2022002433A (es) Análogos de compstatina y sus usos médicos.
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
MX2025001402A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
EP1502949A4 (en) ANTIMICROBIAL POLYPEPTIDE AND USE THEREOF
EA202192925A1 (ru) Твердые формы ингибитора glyt1
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
SE0301431D0 (sv) Novel antimicrobial peptides
EP2435465B1 (en) Methylglyoxal-scavenging compounds and their use for the prevention and treatment of pain and/or hyperalgesia
CY1112839T1 (el) Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ
CN116888146A (zh) 胰高血糖素样肽-1受体拮抗剂
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
EA202192793A1 (ru) Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
MX2023004631A (es) Formulaciones peptidicas y usos oftalmicos de las mismas.
AU2008237138B2 (en) Methods of use of gamma inhibitor compounds for the attenuation of pain
EP2089419A2 (en) Inhibition of beta-amyloid aggregation
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
SE9700301D0 (sv) New compound
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
FR3071504B1 (fr) Produit biologique pour ameliorer la stabilite proteique de boissons a base de mouts vegetaux
MX2025006981A (es) Composiciones para el cuidado personal